Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues.
We have investigated the potential for using anti-sense non-ionic methylphosphonate oligonucleotide analogues to study the relationship between oncogene expression and maintenance of the transformed phenotype in malignant cells. Our results confirmed that the methylphosphonates are resistant to biochemical degradation and are devoid of non-specific toxicity towards cultured human HT29 cells. At low temperature (less than 5 degrees C) both N-ras anti-sense and nonsense analogue 9-mers formed 1:1 complexes in solution with an N-ras sense phosphodiester oligodeoxynucleotide 20-mer, but these were largely dissociated at 25 degrees C. Only a fraction (10-20%) of the anti-sense molecules formed stable sequence specific hybrids (Tm 34 degrees C) with the 20-mer. The biological activity of the oligonucleotide analogues was tested in cell culture at 37 degrees C using T15 cells, a line of NIH 3T3 cells transfected with multiple copies of the human N-ras oncogene under control of the glucocorticoid inducible MMTV promoter. On balance the N-ras anti-sense methylphosphonate 9-mer (20-80 microM) had no effect on these cells. In only one of five experiments was an apparent reduction in dexamethasone-induced p21N-ras protein accumulation observed in the presence of the oligonucleotide analogue. Also without effect was an anti-sense 20-mer consisting of a phosphodiester sequence bounded by two methylphosphonate linkages at each end (25-50 microM in culture media; 4.8 microM by microinjection). We conclude from these experiments that, in order to achieve pronounced effects on oncogene expression, it may be necessary to use longer anti-sense methylphosphonate chains, affinity purified for their ability to hybridize with the target sequences.
Tidd
D M
DM
Cancer Research Campaign Department of Radiation Oncology, University of Liverpool.
Hawley
P
P
Warenius
H M
HM
Gibson
I
I
D001483:Base Sequence; D002460:Cell Line / Q000187:drug effects; D003062:Codon; D003907:Dexamethasone / Q000494:pharmacology; D006801:Humans; D009693:Nucleic Acid Hybridization; D009841:Oligonucleotides / Q000494:pharmacology*; D009857:Oncogenes; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis*; D016283:Proto-Oncogene Proteins p21(ras); D012313:RNA; D018075:RNA, Complementary; D014407:Tumor Cells, Cultured
D003062:Codon; D009841:Oligonucleotides; D011518:Proto-Oncogene Proteins; D018075:RNA, Complementary; D012313:RNA; D003907:Dexamethasone; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)